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Summary Objective: In many countries, universities require students to either
show a physician-certiﬁed proof of immunity or to get vaccinated against measles,
mumps, rubella and varicella, prior to their registration in medical and paramed-
ical majors. The objective of this study was to evaluate the need to implement
this policy in Lebanon. Design: A cross-sectional study was performed on stu-
dents of the Lebanese University (LU), faculties of Medicine, Dentistry, Pharmacy
and Public Health. Methods: The serological immunity status was assessed by
determining speciﬁc antibody titer and the disease and vaccination history of
502 students was collected. Based on percentages of susceptibility, a cost-
effectiveness analysis was performed to compare systematic vaccination without
prior serological testing with selective vaccination of seronegative students. Results:
Percentages of individuals with serologically conﬁrmed immunity against varicella,
measles, rubella and mumps were 93%, 86%, 88% and 75% respectively, and 42%
of the students were susceptible to at least one of the pathogens covered by
the MMR vaccine. Compilation of 186 vaccination records indicated that only
19 students (10%) had been adequately vaccinated. Moreover, among those, 7
students (37%) were still unprotected against at least one virus. Systematic vac-
cination against MMR was found to be 4—5 times less expensive than selective
vaccination, while selective vaccination of seronegative individuals was more cost-
efﬁcient for varicella. Conclusion: Since, in this population, very few individuals
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were able to present a proof of adequate vaccination, it is recommended to systemat-
ically vaccinate healthcare students in Lebanon against MMR. For varicella, selective
vaccination after serological testing should be performed.
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corresponded to all consenting students attending
the last academic year prior to hospital training,
regardless of age, gender, or declared vaccination© 2011 King Saud Bin Ab
Ltd. All rights reserved.
Introduction
Measles, mumps, rubella and varicella are vaccine
preventable diseases that may result in signiﬁcant
morbidity and mortality. Potential complications of
these infections are more severe and more fre-
quent in adults than in children. They include, but
are not limited to, measles-associated encephali-
tis [1], orchitis caused by mumps [2], congenital
malformation in fetuses of rubella-infected moth-
ers [3] and giant-cell pneumonia following varicella
infection [4]. As they are transmitted by the res-
piratory route, they present a high occupational
risk for healthcare providers and for the patients
with whom they may come in contact. Many reports
account for hospital transmission of measles and
varicella [5—7]. Even though mumps and rubella are
less contagious, outbreaks may also occur and can
result in a heavy ﬁnancial burden on the healthcare
institution [8] or have considerable health conse-
quences on high-risk populations, as is the case for
rubella in pregnant women [9]. This has prompted
ofﬁcial authorities in many countries to introduce
speciﬁc measures to ensure immunocompetence of
hospital personnel. In Europe and the US, for exam-
ple, medical and paramedical students are required
to show evidence of immunocompetence or to be
vaccinated prior to their hospital training [10,11].
In the Middle East region, the incidence and
the risk of outbreak of these diseases are still sig-
niﬁcant [12—14]. The Lebanese Ministry of Health
(MOPH) is actively promoting vaccination against
measles, mumps and rubella. In 1985, with the
cooperation of the World Health Organization and
the United Nations International Children Emer-
gency Fund (UNICEF), Lebanon joined the Expanded
Program on Immunization (EPI) of children vac-
cination regarding measles vaccine [15]. Since
1995, the MOPH has adopted the following ofﬁ-
cial vaccination calendar: a ﬁrst measles vaccine
is administered at the age of 9 months, followed
by a measles—mumps—rubella (MMR) vaccine at the
age of 12—15 months and a booster MMR vaccine at
the age of 4—6 years [16]. When measles vaccine
is not available, MMR vaccine is administered at
9—11 months. These vaccines are available free of
charge in dispensaries. The last report of the MOPH
estimates that MMR vaccine coverage in children 15
months of age is 79% [17]. When it reaches 90%, the
s
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OPH is intends to eliminate vaccination against
easles at the age of 9 months. In parallel, vac-
ination campaigns were launched against measles
n 1987, 1990, 1994 and 2000. They were followed
y two campaigns in 2001 and 2008 where children
eceived a dose of measles—rubella vaccine [18].
n the other hand, no vaccination campaigns have
argeted mumps, and the varicella vaccine has not
et been added to the ofﬁcial vaccination calen-
ar. Moreover, there are no school requirements for
accination against MMR in Lebanon. Therefore, the
ercentage of young adults who are still suscepti-
le to one or more of these diseases is currently
nknown and there are no ofﬁcial recommendations
or the vaccination of healthcare workers.
The objective of this study was to evaluate
he need for the implementation of a policy that
ould ensure immunocompetence of medical and
aramedical students in Lebanon against measles,
umps, rubella and varicella, and to deﬁne the
trategy of this policy. For this purpose, the serolog-
cal immunity of the Lebanese University students
as determined towards these four agents and the
alidity of the self-reported history of disease and
hat of the vaccination booklet data was assessed
s surrogate indicators of immunity. The cost of two
lternative vaccination policies were compared,
ne based on systematic vaccination irrespective
f immune status and the other on selective vacci-
ation of susceptible individuals.
aterial and methods
tudy design and population
cross sectional study was performed, involving
tudents of the Lebanese University (LU). This pub-
ic university is the largest and most widespread
nstitution of higher education in Lebanon. Students
ttending the faculties of Medicine, Dentistry, Phar-
acy and Public Health (departments of Nursing,
idwifery, Physiotherapy and Laboratory Sciences)
ere enrolled. The clusters of selected participantstatus. The study was reviewed and approved by
n Ethical Committee appointed by the Lebanese
niversity.
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-rotecting Lebanese students against MMRV
rocedure and questionnaire
n every cluster, an oral presentation about the
cope of the study was made in classrooms and stu-
ents were invited to enroll. The written informed
onsent of the students to participate in the study
as obtained. Participants ﬁlled out a question-
aire about their socio-economical background,
heir region of origin and residency, and their dis-
ase and vaccination history. They also provided a
opy of their vaccination booklet when available.
etermination of serological protection
tatus
ll blood drawings were performed between
ovember 2007 and April 2008. Blood samples were
llowed to clot overnight and serum was collected,
nd frozen in aliquots at −26 ◦C until use. Deter-
ination of speciﬁc antibody concentration against
ach virus (measles, mumps, rubella and varicella)
as performed by Enzyme-linked Immunosorbent
ssay (ELISA), using the Euroimmun® quantitative
ssay kits (Euroimmun, Lübeck, Germany). In these
ssays, the antigen source is provided by inac-
ivated lysates of in vitro-infected cells. Brieﬂy,
0l of serum (diluted 1:100) were incubated in
ells of Ag-coated microtitration plates for 1 h.
ach plate included negative and positive controls
nd three calibrators of known antibody concen-
rations (expressed in IU/ml or RU/ml). Antibody
inding was revealed by subsequent addition of
eroxidase-labeled goat anti-human IgG antibody,
or 30min, followed by tetramethyl-benzidine sub-
trate. Enzymatic reaction was stopped with 0.5M
ulfuric acid. Optical density was read at 450 nm.
peciﬁc antibody concentration for each serum was
etermined by extrapolation from the calibration
urve. Immunity status was determined from the
ntibody concentration, according to the kits’ man-
facturer guidelines, as follows:
Measles: <200mIU/ml: negative;
200—274mIU/ml: borderline; ≥275mIU/ml:
positive.
Mumps: <16 RU/ml: negative; 16—21RU/ml: bor-
derline; ≥22 RU/ml: positive.
Rubella: <8 IU/ml: negative; 8—10 IU/ml: border-
line; ≥11 IU/ml: positive.
Varicella: <80mIU/ml: negative; 80—109mIU/ml:
borderline; ≥110mIU/ml: positive.Testing of all borderline sera was repeated to
erify ﬁnal status. Sera that were found repeatedly
orderline were considered negative.127
ata management and analysis
ata entry and analysis were performed using the
tatistical Package for Social Sciences (SPSS), ver-
ion 13.0. For qualitative variables, percentages
nd their 95% conﬁdence intervals (95% CI) were
alculated. Chi-squared test (or Bilateral Fisher
xact test in case of expected values <5) was used
or categorical variables. A bivariate analysis was
ndertaken to compare between immune status
f different subgroups; since no signiﬁcant asso-
iation with any sociodemographic characteristic
as found, no multivariate analysis was performed.
appa concordance parameter, sensitivity, speci-
city, positive and negative predictive values were
alculated for different measures. A p-value lower
han 0.05 was considered signiﬁcant.
Data analysis included the following:
Descriptive analysis of all variables (socio-
demographic characteristics, disease and vac-
cination history, serological results): some
continuous variables, namely monthly income
and serological titers were categorized. Immu-
nity status of each individual was classiﬁed
as protected (seropositive), or unprotected
(seronegative).
Subgroup comparison: comparison of serological
immunity was performed according to socio-
economical background, geographical region of
origin or residency, self-reported vaccination or
disease history, or recorded vaccination.
Classiﬁcation of the vaccination booklets data:
for each pathogen, students were classiﬁed in
three groups according to the number of injec-
tions of any vaccine preparation containing the
respective agent: no injection, one injection and
2 or more injections. Within each group, sub-
groups were compared according to the age at
which the vaccines were received: 9—11 months,
12—24 months and after 4 years. According to
the recommendations of the Lebanese MOPH [16],
people were considered adequately vaccinated
against MMR if they were vaccinated at least
twice against all three pathogens.
Cost minimization analysis: This study applied
the cost of vaccines ofﬁcially set by the Lebanese
MOPH, i.e. 13USD/dose for MMR and 33USD/dose
for varicella. The cost of serology tests was esti-
mated from the average rates applied by several
medical laboratories in the country to be 35USD
per pathogen. To estimate the cost of selec-
tive vaccination, this study considered both lower
and higher bounds of the 95% conﬁdence interval
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Figure 1 Serological immunity against pathogens covered by the MMR vaccine MMR vaccine is not required for indi-
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pathogen (42.3%). Speciﬁc susceptibility is detailed in th
concentrations were as follows: measles: ≥275mIU/ml; m
around the percentage of unprotected individuals
found in this study.
Results
Demographical characteristics of the study
population
Out of 648 students solicited, 502 (77%) consented
to enroll in this study. They were recruited from
the faculties of Medicine (78 participants/82 sol-
licited students; 95.1%), Dentistry (35/41; 85.3%),
Pharmacy (n = 36/49; 73.4%) and the following
departments of the Faculty of Public Health:
Nursing (n = 122/170; 71.7%), Laboratory Sciences
(n = 141/180; 78.3%), Physiotherapy (n = 41/69;
59.4%) and Midwifery (n = 49/58; 84.4%). Because of
the high prevalence of females in most paramed-
ical careers, such as nursing and midwifery, the
study population included 408 females (81.3%) and
94 males (18.7%). Median age of the participants
was 20 years (ranging from 17 to 26 years old).
The participants originated from all districts
(mouhafazat) of Lebanon, namely from the North
(n = 117 students), Mount Lebanon (n = 108), the
Bekaa Valley (n = 90), the South (n = 70), Nabatieh
(n = 52), Akkar (n = 33) and Beirut (n = 32). They
belonged to a diversiﬁed socio-economical back-
ground, with a median individual monthly income in
the family of 187,500 LBP with a interquartile range
of [107,143—300,000 LBP] (equivalent of U.S.125 $
[71—200]).
Serological immunity status against
measles, mumps, rubella and varicella
Disease protection status was deduced from speciﬁc
antibody concentration. The study results indicated
o
i
bis required for those who are susceptible to at least one
eakdown of the pie. The minimum protective antibody
ps: ≥22 RU/ml; rubella: ≥11 IU/ml.
hat the protection prevalence was high against
aricella (93.4%; 95% CI [91.2—95.6]), but it was
ower against measles (85.6%; 95% CI [82.5—88.1])
nd rubella (87.9%; 95% CI [85.0—90.8]), and
elatively poor against mumps (75.5%; 95% CI
72.6—78.4]). Since protection against measles,
umps and rubella can be achieved through vac-
ination with the same MMR vaccine, concomitant
rotection against these three pathogens was also
nvestigated. The results of this analysis, illustrated
n Fig. 1, indicate that 42.2% (95% CI [37.9—46.5])
f the total population were susceptible to at least
ne of them, among which 18.9% were susceptible
o mumps alone.
ssociation between serological immunity
nd socio-economical parameters
erological immunity status was correlated with the
uestionnaire data in order to determine if age,
ender, place of residency, education level of the
arents or economical status had an impact on the
rotection status of the participants. No signiﬁcant
ifference in protection percentage against these
iseases was found, according to any of the afore-
entioned parameters (p > 0.05 in all cases).
oncordance between serological immunity
nd self-reported history of disease or
accination
he serological immunity status was compared with
he results of the questionnaire in order to evaluate
he validity of the self-reported history of disease,
r that of vaccination as presumptive proofs of
mmunity.
Among students who reported that they have
een infected in their childhood with measles,
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Table 1 Concordance between declared infection history and serologically conﬁrmed immunity.
Declaration of infection history Serologically conﬁrmed immunity
n (100%) n % p
Measles 0.934
Reported history of infection 193 165 85.5%
No reported history of infection 309 265 85.8%
Total 502 430 85.7%
Concordance coefﬁcienta: Kappa =−0.002; Se = 38.4%; Sp = 61.1%; PPV = 85.5%; NPV = 14.2%
Mumps <0.001
Reported history of infection 205 179 87.3%
No reported history of infection 297 196 66.0%
Total 502 375 74.7%
Concordance coefﬁcienta: Kappa = 0.189; Se = 47.7%; Sp = 79.5%; PPV = 87.3%; NPV = 34%
Rubella 0.462
Reported history of infection 90 77 85.6%
No reported history of infection 412 364 88.3%
Total 502 441 87.8%
Concordance coefﬁcienta: Kappa =−0.011; Se = 17.5%; Sp = 78.7%; PPV = 85.6%; NPV = 11.7%
VARICELLA 0.074
Reported history of infection 302 287 95.0%
No reported history of infection 200 182 91.0%
Total 502 469 93.4%
Concordance coefﬁcienta: Kappa = 0.047; Se = 61.2%; Sp = 54.5%; PPV = 95%; NPV = 9%
a Concordance coefﬁcient was calculated between self-reported history of infection on one hand and serologically conﬁrmed
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NPV: negative predictive value.
ubella or varicella, the positive predictive values
ere not different from those found in people who
id not report previous infection (Table 1). How-
ver, for mumps, the positive predictive value of
rotection was signiﬁcantly associated with a his-
ory of infection (87.3%, versus 66%; p < 0.001),
ndicating that the recall of infection with mumps
s more accurate than that of the other pathogens
Table 1).
Concerning self-reported history of vaccina-
ion, it was considered that when students certify
hat they have received all their childhood vac-
ines, they would assume that they are protected
gainst measles, mumps and rubella (varicella is
ot included in this analysis because the vaccine
as not widely available for this study popula-
ion). As shown in Table 2, there was no signiﬁcant
orrelation between positive predictive values and
eclaration of regular vaccination for any of these
hree pathogens.
oncordance between serological immunity
nd vaccination recordut of 502 enrolled students, 186 (37%) were able
o provide a copy of their vaccination booklet.
s expected, only two students were vaccinated
gainst varicella, since this vaccine was introduced
o
p
v
vSe: sensitivity; Sp: speciﬁcity; PPV: positive predictive value;
n Lebanon only after its approval by the FDA [20] in
995 and is still exclusively available in the private
ector.
Results of vaccination booklet analysis for MMR
re depicted in Fig. 2 and those of their correlation
ith serological protection status are summarized
n Table 3.
Considering measles, records indicate that 173
tudents (93%) have received at least one injec-
ion of measles or MMR vaccine. Out of those, 99
ndividuals were vaccinated once, while 74 were
accinated twice or more. In the ﬁrst group, 80.8%
ad protective antibody titers against measles,
hile this percentage was signiﬁcantly increased
o 91.9% (p = 0.049) in the second group (Table 3).
mong those who received two injections, there
as no signiﬁcant difference in the percentage of
rotected individuals according to the age of vac-
ination (data not shown).
Vaccination coverage for mumps was very low,
s vaccination records showed that 77 students
41.4%) did not receive any vaccine injection, 90
48.4%) received a single injection and only 19
10.2%) received two or more injections. More-
ver, vaccination did not provide signiﬁcantly added
rotection, since 84.2% of individuals who were
accinated twice were protected towards mumps,
ersus 68.8% (p = 0.257) of those who did not receive
130 S. Chamat et al.
Figure 2 Student’s history of vaccination against measles, mumps and rubella. Percentages are calculated for 186
compiled vaccination records. Vaccination is categorized as inexistent when not noted in the record, optimal when
se M
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iin conformity with the recommendations of the Lebane
recommendations.
the vaccine (Table 3). Given the low number of indi-
viduals who received two or more injections, both
categories of vaccinated individuals were pooled
into one population and compared to unvacci-
nated subjects. It was found that seroposivity was
increased (78% versus 68.8%) but the difference
remained non signiﬁcant.
For rubella, vaccination coverage with at least
one injection was 64.5% (120/186). Percentage of
seropositive individuals was 81.8% among those who
did not receive any vaccine preparation contain-
c
a
e
Table 2 Concordance between declared vaccination and s
Declaration of vaccination Serologically
n (100%)
Measles
Assumption of vaccination 397
No assumption of vaccination 105
Total 502
Concordance coefﬁcienta: Kappa = 0.054; Se = 80%; Sp = 26.4%
Mumps
Assumption of vaccination 397
No assumption of vaccination 105
Total 502
Concordance coefﬁcienta: Kappa = 0.038; Se = 80%; Sp = 23.6%
%; Sp = 23.6%; PPV = 75.6%; NPV = 28.6%
Rubella
Assumption of vaccination 397
No assumption of vaccination 105
Total 502
Concordance coefﬁcienta: Kappa = 0.039; Se = 78.5%; Sp = 16.
a Concordance coefﬁcient was calculated between self-reported
immunity (protected versus unprotected status) on the other hand.
NPV: negative predictive value.OPH, or suboptimal if present but not meeting those
ng this virus. This percentage was signiﬁcantly
ncreased to 92.5% (p = 0.028) in vaccinated indi-
iduals, regardless of the number of injections. It
s to be noted that one and two or more injections
esulted in identical percentages of protection.
Taken together, these results highlight two worri-
ome facts. First, out of 186 individuals who turned
n their medical record, only 19 (10.4%) were vac-
inated twice against measles, mumps and rubella
s recommended by the Lebanese MOPH. Second,
ven among those seven (36.8%) were still suscep-
erologically conﬁrmed immunity.
conﬁrmed immunity
n % p
0.217
344 86.6%
86 81.9%
430 85.7%
; PPV = 86.6%; NPV = 18.1%
0.386
300 75.6%
75 71.4%
375 74.7%
; PPV = 75.6%; NPV = 28.6%
0.354
346 87.2%
95 90.5%
441 87.8%
4%; PPV = 87.2%;NPV = 9.5%
history of vaccination on one hand and serologically conﬁrmed
Se: sensitivity; Sp: speciﬁcity; PPV: positive predictive value;
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Table 3 Concordance between recorded vaccination protocol and serologically conﬁrmed immunity.
Vaccination protocol Serologically conﬁrmed immunity
n (100%) n % p
Measles
No injection 13 9 69.2 0.039
One injection 99 80 80.8 0.049
Two or more injections 74 68 91.9 Ref
Total 186 157 84.4 0.030
Concordance coefﬁcienta: Kappa = 0.104; p = 0.022;Se = 43.3%; Sp = 79.3%; PPV = 91.9%; NPV = 20.5%
Mumps
No injection 77 53 68.8 0.257
One injection 90 69 76.7 0.559
Two or more injections 19 16 84.2 Ref
Total 186 138 74.2 0.327
Concordance coefﬁcienta: Kappa = 0.03; p = 0.410; Se = 11.6%; Sp = 93.8%; PPV = 84.2%; NPV = 26.9%
Rubella
No injection 66 54 81.8 0.028
One or more injections 120 111 92.5 Ref
Total 186 165 88.7 0.028
Concordance coefﬁcienta: Kappa = 0.126; p = 0.028; Se = 67.3%; Sp = 57.1%; PPV = 92.5%; NPV = 11.2%
nce c
PV: p
t
m
C
A
t
a
M
a
v
a
t
v
i
(
t
c
1
c
s
t
D
T
o
v
p
n
t
a
s
f
T
i
b
M
s
s
p
w
t
s
T
d
i
h
a
r
s
t
t
o
o
t
da Kappa is the concordance coefﬁcient between the refere
logically conﬁrmed immunity. Se: sensitivity; Sp: speciﬁcity; P
ible to at least one of the three pathogens: two to
easles, two to rubella and three to mumps.
ost minimization analysis
ccording to the results, 7% of students were unpro-
ected against varicella and 42% were unprotected
gainst at least one of the pathogens covered by the
MR vaccine. Considering 95% conﬁdence interval
round these percentages, the cost of systematic
accination of all the students without prior evalu-
tion of their protection status was compared to
hat of serological testing followed by selective
accination. The results, summarized in Table 4,
ndicate that, for MMR, systematic vaccination
2600USD/100 individuals) is more cost effective
han serological testing followed by selective vac-
ination of susceptible students (approximately
1,600USD/100 individuals). However, for vari-
ella, it would cost less to selectively vaccinate
usceptible individuals (approximately 4000USD)
han to blindly vaccinate all students (6600USD).
iscussion
his study was performed to evaluate the extent
f protection against measles, mumps, rubella and
aricella, among the LU students of medical and
aramedical professions, in order to recommend a
ew policy that would ensure their immunocompe-
ence prior to their hospital training.
i
c
p
tategory (compared to other vaccination protocols) and sero-
ositive predictive status; NPV: negative predictive value.
Using ELISA tests to measure speciﬁc serum
ntibodies, it was found that the percentage of
eropositive individuals was 86% for measles, 87%
or rubella, 76% for mumps and 93% for varicella.
hese percentages were similar to those reported
n other studies recently performed in Italy [21]
ut lower than those of other countries of the
iddle-East [22], Europe [23] and USA [24]. In a
imilar study conducted in Lebanon in 1993, 95% of
tudents and nurses of the American University Hos-
ital (AUH) were seropositive for measles, and 84%
ere seropositive for mumps [19]. Consequently,
he results indicate a decline in the proportion of
eropositive young adults over the past 15 years.
his is most probably due to the decline in the inci-
ence of these diseases and subsequent reduction
n the probability of infection.
Evaluation of immunity based on ELISA tests may
ave resulted in underestimation of the percent-
ge of protected individuals. Indeed, it has been
eported that, for measles, ELISA is slightly less
ensitive than the plaque reduction neutralization
est (PRNT) [25,26] that detects functional neu-
ralizing antibodies [27]. Moreover, the absence
f antibodies does not rule out the presence
f speciﬁc cellular immunity that could poten-
ially protect subjects from infection, as has been
emonstrated by Jokinen et al. regarding mumps
mmunity [28]. However, PRNT and evaluation of
ellular immunity are not applicable for routine
re-enrollment screening purposes, while quanti-
ative ELISA is rapid, simple, relatively inexpensive
132 S. Chamat et al.
Table 4 Cost analysis of alternative vaccination policies.
MMR Expected cost for 100 individuals (USD)
Selective vaccination Systematic vaccination
Assuming 37.9% unprotected Assuming 46.5% unprotected
Serologya 10,500 10,500 0
Vaccinationb 985 1209 2600
Total 11,485 11,709 2600
Varicella Assuming 4.4% unprotected Assuming 8.8% unprotected
Serologya 3500 3500 0
Vaccinationb 290 580 6600
Total 3790 4080 6600
Cost effectiveness was calculated considering both lower and higher bounds of the 95% conﬁdence interval around the percentage
of unprotected individuals and for the following costs of serology tests and vaccination, that are applicable in Lebanon.
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b Vaccination cost = 33 USD/dose for varicella and 13 USD/d
and internationally standardized. Underestimating
the proportion of protected individuals has limited
consequences in this study, since outbreaks have
been reported even in medical settings where sus-
ceptibility percentages towards these pathogens
were low [29]. This highlights the need for imme-
diate measures to achieve immunocompetence of
healthcare students prior to their enrollment in the
workplace.
The results of this study showed that declared
disease or vaccination history in a self-administered
questionnaire was not a sufﬁcient tool for predict-
ing immunity. Only declaration of previous infection
with mumps had a signiﬁcantly increased positive
predictive value of protection. But even then, 13%
of individuals who believed they were protected
against this pathogen were found to be seroneg-
ative. These results conﬁrm previous reports by
Abbas et al. [30] and by Bdour and Batayneh [31]
on other populations of the Middle-East.
In Lebanon, there are no current guidelines
for protection of healthcare workers against these
pathogens, so the possibility of adopting policies
applied in other countries was considered. For
example, in the USA, according to the ACIP-CDC
guidelines, a physician-certiﬁed record of disease
or vaccination is acceptable as a proof of protec-
tion [10]. The feasibility of using these records to
determine protection of students against measles,
mumps and rubella was considered, however, it
was found that this approach is inappropriate for
a number of reasons. First, only 186 students (37%)
were able to turn in their vaccination booklet. It
is to be noted that the use of this booklet is not
actively reinforced in Lebanon. Second, the com-
pilation of available vaccination booklets showed
that only 19 students (10%) were vaccinated at
a
t
s
bella or varicella).
or MMR. Each vaccination consists of two doses.
east twice against all three MMR pathogens as rec-
mmended by the Lebanese MOPH. This could be
ttributed to the fact that, the median age of these
tudents being 20 years, they did not proﬁt from the
ecommendation for the second MMR vaccine dose
hat was introduced in Lebanon in 1995. It is now
stablished that a single MMR dose does not confer
ufﬁcient protection against measles [32,33] and
umps [13]. Given the substantial efforts deployed
y the Lebanese authorities since 1995 to enforce
hildren vaccination against measles and rubella,
t is expected to witness an increase in the protec-
ion status of young adults in the near future against
hese two pathogens. However, mumps would still
emain a signiﬁcant risk for healthcare person-
el because of the low vaccine coverage. It is
herefore of capital importance to reduce as much
s possible the susceptibility to infection prior to
tudent enrollment in hospitals. Finally, seven ade-
uately vaccinated individuals were still found to
e seronegative to at least one of the pathogens
overed by the MMR vaccine.
Consequently, a policy relying on adopting the
ecords of the vaccination booklet as a surrogate
roof of protection to avoid blind vaccination is not
iable: 96.2% of the students would still need to be
accinated (62.9% because they do not have a vac-
ination booklet, and an additional 33.2% because
heir vaccination is not adequate), and among the
.8% that would be exempted, 1.4% would not be
otally protected.
Therefore, in order to achieve maximum pos-
ible protection of healthcare students, only two
lternative policies can be considered: either
o serologically determine immunity status and
electively vaccinate susceptible individuals, or to
lindly vaccinate all students without prior serol-
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[rotecting Lebanese students against MMRV
gy. The cost minimization results indicate that
he ﬁrst approach is most suitable for varicella,
hile the second is to be adopted for MMR. Cur-
ently, there have been few reported side effects
ssociated with vaccination of previously protected
ndividuals when respecting contraindications [34].
or students who prefer not to receive an unnec-
ssary vaccine, it is always possible to perform
erology and vaccinate only if needed.
It is suggested that the authorities of the LU
equire the students to be vaccinated prior to their
egistration and provide the logistic and ﬁnancial
eans to enforce this policy on campus, with the
ooperation of the Lebanese MOPH.
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